What the FDA labels say about taking them together
Clarithromycin and paricalcitol
Paricalcitol's FDA label of August 7, 2024 names clarithromycin in its drug interactions section; the clarithromycin label PlainMeds reads does not name paricalcitol. The paricalcitol label: “… coadministration with strong CYP3A inhibitors such as but not limited to: boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone …”
Check it at the source: the clarithromycin FDA label on DailyMed (effective April 9, 2026, Solaris Pharma Corporation); the paricalcitol FDA label on DailyMed (effective August 7, 2024, AbbVie Inc.).
What does the clarithromycin label say about paricalcitol?
Clarithromycin's label (effective April 9, 2026) does not name paricalcitol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Clarithromycin), Solaris Pharma Corporation, effective April 9, 2026 (SPL set 4d42821d-ce7a-7d64-e063-6294a90a0875), via openFDA; the full label on DailyMed
What does the paricalcitol label say about clarithromycin?
Paricalcitol label, drug interactionsClinical Impact; Paricalcitol is partially metabolized by CYP3A. Hence, exposure of paricalcitol will increase upon coadministration with strong CYP3A inhibitors such as but not limited to: boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole.
Zemplar label (AbbVie Inc., August 1, 2024), drug interactionsExamples; Boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, and voriconazole
Source: FDA drug label (Zemplar, NDA020819), AbbVie Inc., effective August 1, 2024 (SPL set 7259652f-81bc-4ad1-bba5-d01f9fac1b80), via openFDA
Source: FDA drug label (Paricalcitol, NDA207174), Accord Healthcare, Inc., effective July 30, 2024 (SPL set 2b7c7587-2042-0d9c-e054-00144ff88e88), via openFDA
Source: FDA drug label (Zemplar), AbbVie Inc., effective August 7, 2024 (SPL set 1b27c026-2d60-47b4-2a9c-ded1818f21b5), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clarithromycin | Paricalcitol | |
|---|---|---|
| Labeled for | Bacterial infections, Acid reflux and ulcers | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.466 per tablet 500 mg tablet | $1.28 per capsule 1 mcg capsule |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once